Neuro-Oncology Advances (NOA) paper ...Remember that one back in June?
Closer and closer to the GBM indication, as we wouldn't have been given the priviledge to be invited among the first to publish in the new NOA journal ...
It's just a matter of when. Not if.
And UHN is placing its top influencers at the right place ... for us to obtain credibility and visibility at proper time.
Thanks to NOA
Editor-in-Chief UHN's Dr. Gelareh Zadeh (SNO) Gelareh Zadeh, MD, PhD - Society for Neuro-Oncology 2018 -
Vice President - SNO
2019 -
President - SNO
Oct. 4, 2019 ...
Congratulations to Dr. Gelareh Zadeh @UHN for being elected president of the Society for Neuro-Oncology Gelareh Zadeh | UHN Research
... we made the 1st edition of the brand new NOA journal:
Efficacy of ruthenium coordination complex–based Rutherrin in a preclinical rat glioblastoma model Abstract
Background
Glioblastoma is an aggressive brain cancer in adults with a grave prognosis, aggressive radio and chemotherapy provide only a 15 months median survival.
Methods
We evaluated the tolerability and efficacy of the Ruthenium-based photosensitizer TLD-1433 with apo-Transferrin (Rutherrin) in the rat glioma 2 (RG-2) model. The specific tumor uptake ratio and photodynamic therapy (PDT) threshold of the rat glioblastoma and normal brain were determined, survival and CD8+T-cell infiltration post-therapy were analyzed. Results were compared with those obtained for 5-aminolevulinic acid (ALA)-induced Protoporphyrin IX (PpIX)-mediated photodynamic therapy in the same animal model. As both photosensitizers have different photophysical properties, the number of absorbed photons required to achieve an equal cell kill was determined for in vitro and in vivo studies.
Results
A significantly lower absorbed energy was sufficient to achieve LD50 with Rutherrin versus PpIX-mediated PDT. Rutherrin provides a higher specific uptake ratio (SUR) >20 in tumors versus normal brain, whereas the SUR for ALA-induced PpIX was 10.6. To evaluate the short-term tissue response in vivo, enhanced T2-weighted magnetic resonance imaging (MRI) provided the spatial extent of edema, post PpIX-PDT at twice the cross-section versus Rutherrin-PDT suggesting reduced nonspecific damage, typically associated with a secondary wave of neuronal damage. Following a single therapy, a significant survival increase was observed in rats bearing glioma for PDT mediated by Rutherrin versus PpIX for the selected treatment conditions. Rutherrin-PDT also demonstrated an increased CD8+T-cell infiltration in the tumors.
Conclusion
Rutherrin-PDT was well tolerated providing a safe and effective treatment of RG-2 glioma.
About the Journal
Neuro-Oncology Advances is intended to expand the scope and spectrum of what Neuro-Oncology journal covers. NOA is an open access inter-disciplinary journal encompassing basic, applied, and clinical investigations in all research areas as they relate to cancer and the central nervous system. It provides a single forum for communication among neurologists, neurosurgeons, radiotherapists, medical oncologists, neuropathologists, neuroradiologists, and researchers together with educators. NOA will be publishing high-quality research after the same exceptional-standards of peer-review and editorial process that the field receives from Neuro-Oncology; however, NOA may not always apply the same criteria for novelty that may be a factor in acceptance decisions for Neuro-Oncology. NOA will serve to increase accessibility to areas of research outside of the scope of Neuro-Oncology.
NOA aims to publish research from all disciplines that are interested in advancing outcomes of brain, spine and peripheral nerve tumors. It focuses to capture investigative advances in areas that have traditionally fallen outside of Neuro-Oncology. The following broad priorities will encompass clinical, investigative and basic science research, bioinformatics and computational science analysis, clinical and surgical trials, technology and engineering.
SCOPE
1. High-quality research on primary brain malignancies, noting that studies with negative outcomes are also valuable for the field and confirmatory studies are increasingly important.
2. Brain metastases, cancer-related neurological events and advances in management of brain metastases and cancer in general to prevent brain metastases.
3. Non-malignant nervous system tumors including meningiomas, schwannomas, pituitary tumors, spinal and peripheral nerve tumors.
4. Technological advances in surgery, radiation therapy, radiosurgery and imaging
5. Bioinformatics and computational advances in large data analyses related to subjects within our scope.
6. Spinal tumors and spine metastases.